| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
Coumarin 7 does not have a specific pharmacological target. It is a fluorescent probe used for imaging and detection. Its mechanism of action is based on its fluorescent properties, which allow it to be used as a tracer in various experimental applications. It can bind to specific molecules or structures within cells, enabling their observation and tracking.
|
|---|---|
| ln Vitro |
The highest luminescence intensity (Imax=0.39×10-9 photons/smL), total light amount (S=0.07×10-10 photon/mL), and CL yield (φCL=0.12×108 Einstein/mol) are all found in coumarin 7 [2].
In vitro, Coumarin 7 exhibits antiviral activity against the X4 tropic HIV-1 clone pNL4-3 in H9 cells with an IC50 of 240.0 nM. It shows low cytotoxicity with a CC50 greater than 50,000.0 nM. It is also used as a fluorescent dye in various research applications. |
| ln Vivo |
In vivo, Coumarin 7 is used as a fluorescent probe for imaging applications. It is being explored in photodynamic therapy as a photosensitizer, where it can generate reactive oxygen species upon light activation, selectively targeting cancer cells.
|
| Enzyme Assay |
Non-cellular assays for Coumarin 7 are based on its fluorescence. Its fluorescent properties are characterized by measuring its absorption and emission spectra. It can be used as a standard in fluorescence spectroscopy. Its photophysical properties, such as quantum yield and lifetime, can be measured.
|
| Cell Assay |
In vitro cellular assays for Coumarin 7 are used for imaging and cell tracking. Cells are incubated with the dye, and its intracellular localization is observed using fluorescence microscopy or flow cytometry. Its effects on cell viability can be assessed using standard cytotoxicity assays. Its antiviral activity is assessed in virus-infected cell cultures.
|
| Animal Protocol |
In vivo animal experiments with Coumarin 7 are conducted for imaging studies. The compound can be injected into animals, and its distribution and accumulation in tissues can be tracked using in vivo imaging systems. Its potential as a photosensitizer for photodynamic therapy could be evaluated in tumor-bearing mouse models.
|
| ADME/Pharmacokinetics |
Coumarin 7 has a molecular weight of 333.38. It is a solid that should be protected from light. It is soluble in organic solvents. Its pharmacokinetic properties would depend on the formulation and route of administration for imaging studies.
|
| Toxicity/Toxicokinetics |
Coumarin 7 shows low cytotoxicity (CC50 > 50,000 nM). However, comprehensive toxicological data are not extensively published. The compound is intended for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
Coumarin 7 is a fluorescent dye and a laser dye. It exhibits blue-green fluorescence and is used as a fluorescent probe for biomolecule labeling and cellular imaging. It has demonstrated antiviral activity against HIV-1 with low cytotoxicity and is being explored as a photosensitizer for photodynamic therapy.
|
| Molecular Formula |
C20H19N3O2
|
|---|---|
| Molecular Weight |
333.3838
|
| Exact Mass |
333.148
|
| CAS # |
27425-55-4
|
| PubChem CID |
94381
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.302 g/cm3
|
| Boiling Point |
602.3ºC at 760 mmHg
|
| Melting Point |
234-237 °C(lit.)
|
| Flash Point |
318ºC
|
| Vapour Pressure |
1.85E-14mmHg at 25°C
|
| Index of Refraction |
1.692
|
| LogP |
4.182
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
531
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
GOLORTLGFDVFDW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19N3O2/c1-3-23(4-2)14-10-9-13-11-15(20(24)25-18(13)12-14)19-21-16-7-5-6-8-17(16)22-19/h5-12H,3-4H2,1-2H3,(H,21,22)
|
| Chemical Name |
3-(1H-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~74.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9996 mL | 14.9979 mL | 29.9958 mL | |
| 5 mM | 0.5999 mL | 2.9996 mL | 5.9992 mL | |
| 10 mM | 0.3000 mL | 1.4998 mL | 2.9996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
